Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Anti-VEGF Therapies in Retinal Disorders: Current Landscape and Future Directions
by
Sheth, Jay
in
Anti–vascular endothelial growth factor
/ Biosimilars
/ Macular neovascularization
/ Optical coherence tomography
2026
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Anti-VEGF Therapies in Retinal Disorders: Current Landscape and Future Directions
by
Sheth, Jay
in
Anti–vascular endothelial growth factor
/ Biosimilars
/ Macular neovascularization
/ Optical coherence tomography
2026
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Anti-VEGF Therapies in Retinal Disorders: Current Landscape and Future Directions
Journal Article
Anti-VEGF Therapies in Retinal Disorders: Current Landscape and Future Directions
2026
Request Book From Autostore
and Choose the Collection Method
Overview
Anti-vascular endothelial growth factor (anti-VEGF) therapy has transformed the management of macular neovascularization and other retinal vascular disorders; however, treatment burden, variable response, and cost continue to limit real-world outcomes. This Commentary presents an evidence synthesis from a curated collection of articles, focusing on three intersecting priorities: expanding access through biosimilars with comparable efficacy and safety profiles; optimizing treatment through individualized agent selection and faricimab switching paradigms; and leveraging quantitative multimodal imaging biomarkers, including advanced en-face optical coherence tomography fluid metrics, to refine disease monitoring and retreatment decisions. Emerging structural and angiographic biomarkers, including advanced en-face optical coherence tomography metrics, offer opportunities for earlier risk stratification and personalized care. In parallel, patient-centered considerations and pragmatic treatment algorithms remain essential to enhance adherence and durability of response. Together, these themes underscore a shift toward precision-guided, accessible, and evidence-based retinal care. Prospective validation and implementation research will be critical to translate these advances into sustainable clinical practice.
Publisher
Dove Press,Dove Medical Press
This website uses cookies to ensure you get the best experience on our website.